Vibegron (RVT-901/MK-4618/KRP-114V) Administered Once Daily as Monotherapy or Concomitantly with Tolterodine in Patients with an Overactive Bladder: A Multicenter, Phase IIb, Randomized, Double-blind, Controlled Trial.

Background: Antimuscarinics have shown modest efficacy with unwanted side effects in patients with overactive bladder (OAB). Efficacy of vibegron, a new β3-adrenergic receptor agonist, for OAB is unknown.

Objective: To evaluate the efficacy of once-daily oral vibegron in OAB patients (primary), and its safety, tolerability, and efficacy when administered alone or concomitantly with tolterodine (secondary).

Authorship issues at a New Zealand academic institution.

Background: Authorship of peer-reviewed publications can create conflict among academics.

Objective: To document authorship conflicts of academics at a tertiary faculty.

Methods: An anonymous questionnaire eliciting authorship conflicts and knowledge of authorship criteria was administered online to 154 academic staff members at a New Zealand university.

Efficacy of Solifenacin on Overactive Bladder Symptoms, Symptom Bother, and Other Patient-Reported Outcomes in Subjects With or Without Incontinence: A Post Hoc Analysis of Data From VIBRANT.

Objective: : To evaluate the efficacy of solifenacin versus placebo by baseline continence status using post hoc analysis.

Methods: : Patients with overactive bladder (OAB) were randomized to solifenacin or placebo for 12 weeks; patient-reported outcome (PRO) measures and bladder diaries were completed at prespecified time points. VESIcare Investigation of Bother and Quality of Life in Subjects with OAB (VIBRANT) was not designed to show treatment differences within continence status subgroups.

Effects of solifenacin on overactive bladder symptoms, symptom bother and other patient-reported outcomes: results from VIBRANT - a double-blind, placebo-controlled trial.

Aim: The aim of this study was to evaluate the efficacy of solifenacin on symptom bother using the Overactive Bladder Questionnaire (OAB-q).

Methods: In VIBRANT, a double-blind, US-based trial, patients with OAB for > or = 3 months received flexibly dosed solifenacin or placebo for 12 weeks. At baseline and 4-week intervals, patients completed the OAB-q [symptom bother and health-related quality of life (HRQL) scales] and 3-day bladder diaries; other patient-reported outcome measures were also assessed at baseline and week 12.

Ureteral duplication with lower pole ectopia to the vas: a case report of an exception to the Weigert-Meyer law.

We report an unusual case of ureteral duplication with lower-pole ectopia and ureterolithiasis, which violates the Weigert-Meyer law. The duplicated ureter arose from a lower-pole calyx and drained inferiorly into the ipsilateral vas. A presentation of the case is followed by a comparison to the only known similar one, reported in 1988.

Fine needle aspiration biopsy in the diagnosis of renal angiomyolipoma.

Exclusive reliance on radiographic techniques for the diagnosis of renal angiomyolipoma can lead to misdiagnosis when the histological status is atypical, computerized tomographic findings are equivocal or renal cell carcinoma coexists. We report our experience and those of others in combining fine needle aspiration biopsy and radiological imaging to identify renal angiomyolipoma. Fine needle aspiration biopsy is safe and provides accurate histological diagnosis of renal angiomyolipoma.

Human hypervariable sequences in risk assessment: rare Ha-ras alleles in cancer patients.

A variable tandem repeat (VTR) is responsible for the hyperallelism one kilobase 3' to the human c-Ha-ras-1 (Ha-ras) gene. Thirty-two distinct restriction fragments, comprising 3 allelic classes by frequency of occurrence, have thus far been detected in a sample size of approximately 800 caucasians. Rare Ha-ras alleles, 21 in all, are almost exclusively confined to the genomes of cancer patients (p less than 0.

Multifocal pigmentation of prostatic and bladder urothelium.

Multifocal pigmentation of the bladder and prostatic urothelium is described in 2 white men. The light microscopic, electron microscopic and histochemical characterization of these foci identified the contained pigment as melanin.

Human restriction fragment length polymorphisms and cancer risk assessment.

The polymorphic restriction fragments of the human Ha-ras locus, produced by the variable tandem repetition (VTR) of a short consensus sequence, fall into three classes based on allelic frequencies. Alleles of the "rare" class (individual frequencies less than 0.5%) have been detected only in white blood cell and tumor DNA of cancer patients.

Computed tomography differentiation of pyelonephritis and renal infarction.

Acute renal infarction and acute pyelonephritis can have identical clinical presentations. Most of the computed tomography findings seen in acute renal infarction are similar to those in acute pyelonephritis, except for the characteristic cortical rim sign seen in acute infarction. This finding differentiates these two disorders.

Determination of the chemical composition of urinary calculi by computerized tomography.

The clinical management of renal calculi would be aided if a direct in vivo determination of stone chemical composition could be made. We investigated the possibility of obtaining this information by a quantitative analysis of the computerized tomography scan images of 80 urinary calculi. Our results show that by using an appropriately calibrated computerized tomography scanner the differentiation of stone chemical composition can be made on the basis of 3 parameters, namely, absolute computerized tomography value at a single x-ray energy, the difference between computerized tomography values measured at 2 different x-ray energies, and computerized tomography value-frequency histograms (pixel patterns) of the stones.

Management of the bladder by augmentation ileocecocystoplasty.

Use of cecum and ileum to construct a large capacity, urinary reservoir with provision for easy intermittent catheterization is described. The technique is useful in the management of hypertonic or hyperreflexic vesical dysfunction.

Proliferative glomerulonephritis in mice given intravenous Corynebacterium parvum.

Mice given a killed suspension of Corynebacterium parvum (C.p.) developed nephritis as part of an immune complex disease.

Immune-complex disease in mice and humans given C. parvum.

The present studies in mice and cancer-bearing patients, treated with C. parvum (CP) immunotherapy, were to determine the effects of CP on the production of immune complexes (IC) and associated disease. Using the Clq-binding assay, circulating immune complexes were detected in mice given a single high dose of CP (466 microgram) and repeated human-equivalent doses (70 microgram).

Single versus multiple human-equivalent doses of C. parvum in mice: neutralization of the anti-metastatic effect.

The murine dose of i.v. C.

Mechanisms of C. Parvum-induced coagulopathy in mice.

I.v. injection of Corynebacterium parvum (CP) into C57BL and BALB/c mice caused profound coagulation changes, featuring thrombocytopenia, decreased fibrinogen, increased fibrin/fibrinogen degradation products, and a concomitant microangiopathic haemolytic anaemia.

Transplantation for polycystic kidney disease.

Twenty-four patients with end stage renal failure due to polycystic renal disease have been treated with hemodialysis and transplantation. While on dialysis, the incidence of complications did not differ from a similar group of patients with other causes of renal failure. Bilateral pretransplant nephrectomy is not mandatory except in cases of persistent infection or hemorrhage.

Clinical aspects of polycystic disease of the kidneys.

Seventy-eight patients were treated for polycystic disease of the kidneys. An analysis of the interval between the onset of symptoms and end-stage renal failure made it possible to give and accurate prognosis in individual cases. Pregnancy and urinary infection did not appear to accelerate deterioration of renal function, but Rovsing' operation precipitated renal failure in some cases.

Clinical studies with Corynebacterium parvum.

In a pilot study twelve patients with malignant disease were treated with Corynebacterium parvum. The clinical results were encouraging. A prospective randomised controlled clinical trial of C.